VIDEO: Mirvetuximab plus bevacizumab demonstrates 'impressive' results in ovarian cancer
Click Here to Manage Email Alerts
In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, spoke with Healio about mirvetuximab, which “has generated considerable excitement and interest as an anti-ovarian cancer agent.”
Specifically, Rubin cited a study presented at the ASCO Annual Meeting that assessed the antitumor activity of mirvetuximab when combined with bevacizumab in both patients with platinum-resistant and platinum-sensitive, or platinum-agnostic, ovarian cancer.
In the trial, the combination of mirvetuximab and bevacizumab demonstrated “impressive antitumor activity with durable responses and favorable toxicity in patients with recurrent ovarian cancer with high expression of folate receptor levels,” Rubin said, noting that it suggests an ongoing role for this treatment combination in these patients.
Collapse
O’Malley DM, et al. Abstract 5504. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts